EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in North America, is investing $12 million to expand its R&D facility in Billerica, MA. The new building will have more than 30,000 sq.-ft. and will accommodate approximately 120 new and current employees, with a R&D focus on oncology, immuno-oncology and immunology.   Construction is scheduled to begin in May 2016 with a planned completion date of June 2017.   “The purpose of this expansion is to adv...